Absci Corporation announced positive interim data from its Phase 1 HEADLINE™ trial for ABS-201, an investigational antibody for androgenetic alopecia (hair loss). The results from the single ascending dose (SAD) cohorts showed a favorable safety profile and a long half-life, supporting the trial's advancement to the multiple ascending dose (MAD) phase.
Key Details
- Drug & Indication: ABS-201 is a novel antibody targeting the prolactin receptor (PRLR) for the treatment of androgenetic alopecia.
- Safety Profile: The drug was well-tolerated across all four SAD cohorts (32 participants), with no serious adverse events reported as of the June 8, 2026 data cutoff.
- Pharmacokinetics: ABS-201 demonstrated an estimated half-life of at least 65 days, supporting a potential dosing interval of two or three injections over a six-month period.
- Next Steps: The trial has advanced to the MAD portion. Absci anticipates interim proof-of-concept data in H2 2026 and full proof-of-concept data in early 2027.